BRUIN CLL-313 showed significantly longer progression-free survival vs bendamustine plus rituximab, bringing a noncovalent BTK inhibitor to first-line care.
|Articles|February 14, 2020
- February 2020
- Volume 87
- Issue 2
Pharmacists Introduced the Soda Fountain, An American Icon
Author(s)Karen Berger, PharmD
In the 19th and 20th centuries, druggists made and marketed their own secret formulas.
Advertisement
A version of this article was originally published on PharmacyTimes.com February, 16 2019. View the full article
Articles in this issue
over 6 years ago
Interactives: Case Studies (February 2020)over 6 years ago
Clinical Pharmacology Update: Xenleta from Nabriva Therapeuticsover 6 years ago
Can a Patient with HIV Maintain a Lawsuit?over 6 years ago
Help Teens Who Struggle With Depressionover 6 years ago
Study Results Link Postpartum Depression to Inflammationover 6 years ago
Clinical Evidence Exists for Allopregnanolone-based Treatmentsover 6 years ago
Pet Peevesover 6 years ago
Nonprofit Addresses Commonsense Prescribingover 6 years ago
Advanced Education and Training Opportunities IncreaseAdvertisement
Related to this article
A behavioral walking program matched supervised aerobic training for improving asthma control in a randomized trial of physically inactive adults.
Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
American Pharmacists Month kicked off on October 1, honoring more than 700,000 pharmacy professionals and 250 years of caring for America's communities.
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
Decades after cisplatin's approval, platinum-based chemotherapy continues to anchor treatment regimens across tumor types, new research finds.
A pharmacist-led collaborative drug therapy management program at NYC Health + Hospitals/Bellevue reported high patient satisfaction, and every surveyed patient said they felt respected and supported by their pharmacist.
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Statin Myths: Why Patients Avoid Cholesterol-Lowering Therapy
2
Tirzepatide Linked to More Weight Loss Than Semaglutide 7.2 mg
3
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
4
Pharmacist, Advocate, Ally: Delivering Comprehensive Gender-Affirming Care
5